cannabidiol
A new weapon against Parkinson’s-related psychosis
December 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, cannabidiol, cannabis, feature, pharma
Dr Arthur Roach, Director of Research at the charity Parkinson’s UK, discusses new trials on cannabidiol in the treatment of …
NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy
August 27, 2019Manufacturing and Production, Sales and Marketing Epidiolex, Epidyolex, GW Pharma, NICE, cannabidiol, cannabis, pharma
UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …
FDA issues warning to CBD company Curaleaf
July 29, 2019Sales and Marketing CBD, FDA, cannabidiol, curaleaf, pharma, regulation
The FDA has issued a warning to Massachusetts-based CBD company Curaleaf over the firm’s use of unsubstantiated claims about the …
Synthetic, non-intoxicating CBD analogue treats seizures in rats
May 31, 2019Medical Communications CBD, H2CBD, cannabidiol, medicinal cannabis, pharma
A synthetic, non-intoxicating cannabidiol (CBD)-analogue is effective at treating seizures in rats, according to researchers at the University of California, …
GW Pharma’s Epidiolex scores in rare childhood onset epilepsy Phase 3 trial
May 7, 2019Manufacturing and Production, Sales and Marketing CBD, Epidiolex, GW Pharma, cannabidiol, cannabis, epilepsy, tsc
GW Pharma’s Epidiolex has shown positive Phase 3 trial results for the fifth time in a row, after meeting primary …
GW Pharma’s Epidiolex becomes first cannabis-based medicine to be made available in United States
November 2, 2018Medical Communications Epidiolex, GW Pharma, Medical marijuana, cannabidiol, cannabis
GW Pharma’s Epidiolex has become the first plant-derived, cannabis-based medicine to be made available on prescription in all 50 US …
GW Pharma’s Epidiolex becomes first cannabis-based medicine available in US
June 26, 2018Manufacturing and Production, Sales and Marketing FDA, GW Pharma, Lennox-Gastaut syndrome, UK, US, cannabidiol, cannabis
In what could prove to be a pivotal decision, UK biotech GW Pharmaceuticals has announced that its oral cannabidiol solution …
FDA issues warnings in crackdown on baseless cannabis miracle cures
November 2, 2017Research and Development, Sales and Marketing FDA, cannabidiol, cannabis, pharma
The FDA has issued a warning over cannabis-based therapies which promise the ability to cure cancer, asserting that such treatments …
Cannabidiol reduces seizures by half in severe epilepsy, study suggests
April 19, 2017Research and Development Lennox-Gastaut syndrome, cannabidiol
A new large-scale study from the American Academy of Neurology has suggested that cannabidiol, a molecule derived from cannabis without …
Cannabis-based treatment scores Phase 3 successes for GW Pharma
December 6, 2016Manufacturing and Production, Research and Development GW Pharma, cannabidiol
UK-based GW Pharmaceuticals, a biopharmaceutical firm focused on the development of novel cannabinoid therapies, has unveiled new efficacy data for …
Late-stage failure for Otsuka and GW cancer pain drug
January 9, 2015Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
Latest content
FibroFind appoints Lee Borthwick as CEO
